With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia ...

Nowell and Hungerford started their search by investigating cells from individuals with acute myelogenous leukemia ... This chromosome was soon dubbed the "Philadelphia chromosome," named after ...

Discovered in 1960, the diagnostic karyotypic abnormality for chronic myelogenous leukemia is shown in this ... breakpoint cluster region [bcr] of chromosome 22 indicated by the arrows).

The FDA has granted accelerated approval to asciminib as a first-line treatment for adults newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia, a rare type of blood cancer.

Suppression of Philadelphia chromosome positivity has been observed ... Current Status of Treatment for Chronic Myelogenous Leukemia. MedGenMed 2(2), 2000 [formerly published in Medscape ...

Danziten, a new formulation of nilotinib, may improve treatment adherence in patients with Philadelphia chromosome-positive ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

was granted accelerated approval by the US Food and Drug Administration for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase or Ph+ ...